Inactive Instrument

Proteo, Inc.

Equities

PTEO

US74369R4074

Biotechnology & Medical Research

Proteo, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019

May 07, 2020 at 06:08 am EDT

Proteo, Inc. announced earnings results for the full year ended December 31, 2019. For the full year, the company announced operating loss was USD 245,212 compared to USD 2,744 a year ago. Net loss was USD 218,167 compared to net income of USD 36,135 a year ago. Basic loss per share from continuing operations was USD 0.01.

Latest news about Proteo, Inc.

U.S. Special Forces launch counter-terrorism drills with African armies	23-03-01	RE
Proteo, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-06-05	CI
Proteo, Inc. Reports Earnings Results for the Full Year Ended December 31, 2019	20-05-07	CI
Proteo, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-14	CI
Proteo, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-05	CI
Proteo, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-14	CI
Proteo, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	19-04-15	CI
Proteo, Inc. Announces Management Changes	18-11-19	CI
Proteo, Inc. and Proteo Biotech AG Announces Final Analysis of the Phase II Clinical Study on Elafin in Coronary Artery Bypass Surgery	14-11-21	CI

Chart Proteo, Inc.

Duration

Period

More charts

Company Profile

Proteo, Inc. is a clinical stage drug development company that is focused on the development of anti-inflammatory treatments for rare diseases. Its drug candidate Tiprelestat (also known as Elafin) is used for the treatment of acute postoperative inflammatory complications, in particular after esophageal cancer surgery. Elafin is also used for the treatment of pulmonary arterial hypertension, for preventing complications of organ transplantation and for treatment of acute respiratory distress syndrome (ARDS). The Company has obtained Orphan drug designations within the European Union for the use of Elafin for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension as well as for the treatment of esophageal cancer. Within the United States, it has obtained Orphan drug designations for the use of Elafin for the treatment of pulmonary arterial hypertension as well as for the prevention of inflammatory complications of transthoracic esophagectomy.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
IQVIA HOLDINGS INC.	+1.69%	42.86B
MODERNA, INC.	+12.82%	42.74B
LONZA GROUP AG	+44.87%	41.36B
CELLTRION, INC.	-8.83%	27.68B
ICON PUBLIC LIMITED COMPANY	+7.50%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-23.42%	18.63B
MEDPACE HOLDINGS, INC.	+29.90%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-2.79%	11.92B
UNITED THERAPEUTICS CORPORATION	+7.33%	11.21B

Other Biotechnology & Medical Research